| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 97.873 | 57.700 | 6.305 | 1.126 | 4 |
| Total Income - EUR | - | - | - | - | - | 97.875 | 57.701 | 6.309 | 1.126 | 4 |
| Total Expenses - EUR | - | - | - | - | - | 72.761 | 66.770 | 14.411 | 5.843 | 775 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 25.114 | -9.069 | -8.102 | -4.717 | -771 |
| Net Profit/Loss - EUR | - | - | - | - | - | 24.135 | -9.506 | -8.162 | -4.726 | -771 |
| Employees | - | - | - | - | - | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Bio Max Pharma Company S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 817 | 1.011 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | 49.412 | 47.604 | 42.646 | 37.290 | 35.845 |
| Inventories | - | - | - | - | - | 10.633 | 25.553 | 24.708 | 23.892 | 23.756 |
| Receivables | - | - | - | - | - | 2.152 | 3.268 | 1.769 | 4.368 | 3.324 |
| Cash | - | - | - | - | - | 36.626 | 18.783 | 16.170 | 9.030 | 8.764 |
| Shareholders Funds | - | - | - | - | - | 24.342 | 14.296 | 6.179 | 1.434 | 655 |
| Social Capital | - | - | - | - | - | 207 | 202 | 203 | 202 | 201 |
| Debts | - | - | - | - | - | 25.886 | 34.318 | 36.468 | 35.856 | 35.190 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Bio Max Pharma Company S.r.l.